Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Heinz Gisslinger, Monika Wroclawska et al.|British Journal of Haematology|2020Cited by 30
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to <100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPANDPaola Guglielmelli, Heinz Gisslinger, Jean‐Jacques Kiladjian et al.|Therapeutic Advances in Hematology|2022Cited by 11
The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to &lt; 100 × 109/L) at BaselinePaola Guglielmelli, Heinz Gisslinger, Jean‐Jacques Kiladjian et al.|Blood|2020Cited by 7
PF679 REAL‐WORLD SAFETY DATA FROM A NONINTERVENTIONAL LONG‐TERM POSTAUTHORIZATION SAFETY STUDY OF RUXOLITINIB IN MYELOFIBROSISFiorenza Barraco, Heinz Gisslinger, Richard Greil et al.|HemaSphere|2019Cited by 0